Juvenile chronic myelocytic leukemia: Experience with intensive combination chemotherapy

Festa, Robert; Shende, Ashok; Lanzkowsky, Philip

doi:10.1002/mpo.2950180411

Cited by 37 publications

(20 citation statements)

References 16 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…43 About 50% of children with MDS treated with intensive chemotherapy enter CR, but only 15% to 30% remain in CR. 15,[44][45][46][47] The present study showed a similar CR rate of 60% in Ϫ7 Ϯ other. Among those who entered CR the OS rate was 43%.…”

Section: Discussionsupporting

confidence: 71%

Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study

Hasle

Alonzo

Auvrignon³

et al. 2007

Blood

130

View full text Add to dashboard Cite

Monosomy 7 (؊7) and deletion 7q [del(7q)]are rare in childhood acute myeloid leukemia (AML). We retrospectively collected data on 258 children with AML or refractory anemia with excess blasts in transformation (RAEB-T) and ؊7 or del(7q) with or without other cytogenetic aberrations [؎ other]. Karyotypes included ؊7 (n ‫؍‬ 90), ؊7 other (n ‫؍‬ 82), del(7q) (n ‫؍‬ 21), and del(7q) other (n ‫؍‬ 65). Complete remission (CR) was achieved in fewer patients with ؊7 ؎ other compared with del(7q) ؎ other (61% versus 89%, P < .001). Overall, the 5-year survival rate was 39% (SE, 3%). Survival was superior in del(7q) ؎ other compared with ؊7 ؎ other (51% versus 30%, P < .01). Cytogenetic aberrations considered favorable in AML [t(8;21)(q22;q22), inv(16)(p13q22), t(15;17)(q22;q21), t(9;11)(p22;q23)] (n ‫؍‬ 24) were strongly associated with del(7q) and a higher 5-year survival rate compared with del(7q) without favorable cytogenetics (75% versus 46%, P ‫؍‬ .03). Patients with ؊7 and inv(3),؊5/del(5q), or ؉21 had a 5-year survival rate of 5%. Stem cell transplantation analyzed as a time-dependent variable had no impact on overall survival. However, patients not achieving CR had a 31% survival rate after stem cell transplantation. Childhood AML with chromosome 7 aberrations represents a heterogeneous group of disorders with additional cytogenetic aberrations having a major prognostic impact which should be reflected in future riskgroup stratification. (Blood. 2007;109: [4641][4642][4643][4644][4645][4646][4647]

show abstract

Section: Discussionsupporting

confidence: 71%

Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study

Hasle

Alonzo

Auvrignon³

et al. 2007

Blood

130

View full text Add to dashboard Cite

show abstract

“…63 ' 64 In the series reported by Castro-Malaspina, 5 no complete remissions were achieved in 38 patients, 33 of whom were treated with conventional chemotherapy. Interestingly however, a dramatic change in the death rate was apparent at 2 years, suggesting that there are two subgroups of patients, the first being the majority of patients whom have a short survival, and the second much smaller group, with a much longer survival.…”

Section: Prognosis and Therapymentioning

confidence: 96%

Juvenile Chronic Myelogenous Leukemia

Hess¹,

Zutter²,

Castleberry³

et al. 1996

Am J Clin Pathol

View full text Add to dashboard Cite

“…Others have also observed that the aggressive chemotherapy used to treat monosomy 7 associated AML in children and young adults results in survival at best in the range of 15%. 6,15,16 Allogeneic marrow transplantation has been the only potentially curative treatment for adult and pediatric patients with MDS. There are few data regarding the outcome of transplantation for children with various types of MDS.…”

Section: Raeb; Raeb-t; Jmml; Cmmlmentioning

confidence: 99%

Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience

Yusuf

Frangoul

Gooley

et al. 2004

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:The purpose of this study was to evaluate the role of allogeneic bone marrow transplantation (BMT) in children with myelodysplastic syndrome (MDS). In total, 94 consecutive pediatric patients with MDS received an allogeneic BMT from 1976 to 2001 for refractory anemia (RA) (n ¼ 25), RA with ringed sideroblasts (RARS) (n ¼ 2), RA with excess blasts (RAEB) (n ¼ 20), RAEB in transformation (RAEB-T) (n ¼ 14), juvenile myelomonocytic leukemia (JMML) (n ¼ 32) or chronic myelomonocytic leukemia (CMML) (n ¼ 1). The estimated 3-year probabilities of survival, event-free survival (EFS), nonrelapse mortality and relapse were 50, 41, 28 and 29%, respectively. Patients with RA/RARS had an estimated 3-year survival of 74% compared to 68% in those with RAEB and 33% in patients with JMML/CMML. In multivariable analysis, patients with RAEB-T or JMML were 3.9 and 3.7 times more likely to die compared to those with RA/RARS and RAEB (P ¼ 0.005 and 0.004, respectively). Patients with RAEB-T were 5.5 times more likely to relapse (P ¼ 0.01). The median follow-up among the 43 surviving patients is 10 years (range 1-25). We conclude that allogeneic BMT for children with MDS is well tolerated and can be curative.

show abstract

Juvenile chronic myelocytic leukemia: Experience with intensive combination chemotherapy

Cited by 37 publications

References 16 publications

Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study

Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study

Juvenile Chronic Myelogenous Leukemia

Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience

Contact Info

Product

Resources

About